Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
View original at globenewswire.comSilexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic tre…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
This progress reflects the strength of our data, the safety demonstrated during the Loder clinical trial, the urgency of the unmet need in pancreatic cancer, and our continued execution toward developing a potentially transformative therapy
60% confidenceThe Phase 2a clinical trial of Loder showed a positive trend in comparison to the control of chemotherapy alone
60% confidenceKRAS mutations are present in over 90% of pancreatic cancers
60% confidenceSilexion plans to advance SIL204 as a potential treatment across additional KRAS-driven indications, including colorectal and lung cancers
60% confidenceWe are now advancing SIL204 into a pivotal clinical trial with the goal of addressing KRAS-driven cancers at their source
60% confidenceSIL204 demonstrated significant anti-tumor activity in multiple preclinical models
60% confidenceThe receipt of this approval marks a defining and highly significant milestone for Silexion
60% confidenceThe Company expects to initiate the Phase 2/3 trial in the second quarter of 2026, subject to site activation and standard clinical readiness procedures
60% confidence